Latebreakers: LMWH gets another indication OK'd

Low molecular weight heparin, enoxaparin (Lovenox, Sanofi-Aventis), has a new indication, the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI).

Related Videos
Related Content

Celebrate Your Story at the American Associated Pharmacies 2023 Annual Conference

March 22nd 2023

Looking to the Future of Independent Pharmacy

July 13th 2022

Meeting Preview: APhA 2023

March 20th 2023

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022

Thoughts From the Streets: The Rise of Xylazine in Illicit Drug Use

March 16th 2023

Show Me the Way: Technician-Led Pharmacy Services

March 10th 2023

Celebrate Your Story at the American Associated Pharmacies 2023 Annual Conference

March 22nd 2023

Looking to the Future of Independent Pharmacy

July 13th 2022

Meeting Preview: APhA 2023

March 20th 2023

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022

Thoughts From the Streets: The Rise of Xylazine in Illicit Drug Use

March 16th 2023

Show Me the Way: Technician-Led Pharmacy Services

March 10th 2023

Celebrate Your Story at the American Associated Pharmacies 2023 Annual Conference

March 22nd 2023

Looking to the Future of Independent Pharmacy

July 13th 2022

Meeting Preview: APhA 2023

March 20th 2023

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022

Thoughts From the Streets: The Rise of Xylazine in Illicit Drug Use

March 16th 2023

Show Me the Way: Technician-Led Pharmacy Services

March 10th 2023
© 2023 MJH Life Sciences

All rights reserved.